Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Notable companies reporting before tomorrow's open » 20:25
10/27/21
10/27
20:25
10/27/21
20:25
MA

MasterCard

$335.50 /

-21.81 (-6.10%)

, CMCSA

Comcast

$52.46 /

-1.29 (-2.40%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

, MRK

Merck

$81.53 /

-0.7 (-0.85%)

, SHOP

Shopify

$1,361.52 /

-2.59 (-0.19%)

, CAT

Caterpillar

$196.10 /

-3.53 (-1.77%)

, BUD

AB InBev

$57.18 /

+0.275 (+0.48%)

, MO

Altria Group

$47.49 /

-0.625 (-1.30%)

, KDP

Keurig Dr Pepper

$34.20 /

-0.37 (-1.07%)

, YUM

Yum! Brands

$125.88 /

-0.43 (-0.34%)

, HSY

Hershey

$179.48 /

-2.48 (-1.36%)

, SWK

Stanley Black & Decker

$186.30 /

-0.375 (-0.20%)

, SIRI

Sirius XM

$5.97 /

-0.08 (-1.32%)

, HBAN

Huntington Bancshares

$15.98 /

-0.5 (-3.03%)

, TAP

Molson Coors

$43.66 /

+0.105 (+0.24%)

, TPX

Tempur Sealy

$46.74 /

-0.88 (-1.85%)

, NLSN

Nielsen

$19.42 /

+0.005 (+0.03%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include MasterCard (MA), consensus $2.19c... Comcast (CMCSA), consensus 75c... Merck (MRK), consensus $1.55... Shopify (SHOP), consensus $1.32... Caterpillar (CAT), consensus $2.20... AB InBev (BUD), consensus 66c... Altria Group (MO), consensus $1.26... Keurig Dr Pepper (KDP), consensus 44c... Yum! Brands (YUM), consensus $1.08... Hershey (HSY), consensus $2... Stanley Black & Decker (SWK), consensus $2.47... Sirius XM (SIRI), consensus 7c... Huntington Bancshares (HBAN), consensus 32c... Molson Coors (TAP), consensus $1.53... Tempur Sealy (TPX), consensus 84c... Nielsen (NLSN), consensus 36c.

ShowHide Related Items >><<
MA MasterCard
$335.50 /

-21.81 (-6.10%)

CMCSA Comcast
$52.46 /

-1.29 (-2.40%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

MRK Merck
$81.53 /

-0.7 (-0.85%)

SHOP Shopify
$1,361.52 /

-2.59 (-0.19%)

CAT Caterpillar
$196.10 /

-3.53 (-1.77%)

BUD AB InBev
$57.18 /

+0.275 (+0.48%)

MO Altria Group
$47.49 /

-0.625 (-1.30%)

KDP Keurig Dr Pepper
$34.20 /

-0.37 (-1.07%)

YUM Yum! Brands
$125.88 /

-0.43 (-0.34%)

HSY Hershey
$179.48 /

-2.48 (-1.36%)

SWK Stanley Black & Decker
$186.30 /

-0.375 (-0.20%)

SIRI Sirius XM
$5.97 /

-0.08 (-1.32%)

HBAN Huntington Bancshares
$15.98 /

-0.5 (-3.03%)

TAP Molson Coors
$43.66 /

+0.105 (+0.24%)

TPX Tempur Sealy
$46.74 /

-0.88 (-1.85%)

NLSN Nielsen
$19.42 /

+0.005 (+0.03%)

MA MasterCard
$335.50 /

-21.81 (-6.10%)

09/29/21 Stephens
Affirm's long-term economic expectations weaker than forecast, says Stephens
09/03/21 Deutsche Bank
Deutsche says many concerns over Visa and MasterCard are minor
08/17/21 JPMorgan
MasterCard price target raised to $430 from $427 at JPMorgan
08/12/21 Daiwa
MasterCard downgraded to Neutral from Outperform at Daiwa
CMCSA Comcast
$52.46 /

-1.29 (-2.40%)

10/13/21 Morgan Stanley
Morgan Stanley says Comcast dropping network a modest near-term negative for MSG
10/12/21 Deutsche Bank
Comcast price target lowered to $64 from $68 at Deutsche Bank
10/11/21
Fly Intel: Top five analyst downgrades
10/11/21 Raymond James
Comcast downgraded to Market Perform from Outperform at Raymond James
CMCSK Comcast
$58.00 /

+ (+0.00%)

02/23/21 Credit Suisse
SeaWorld price target raised to $52 from $34 at Credit Suisse
MRK Merck
$81.53 /

-0.7 (-0.85%)

10/22/21 SVB Leerink
Merck price target raised to $105 from $104 at SVB Leerink
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/19/21 Evercore ISI
Atea's Phase 2 design disappoints, but drug has not failed, says Evercore ISI
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
SHOP Shopify
$1,361.52 /

-2.59 (-0.19%)

10/14/21 TD Securities
TD Securities starts Shopify with Hold, says opportunities seem priced in
10/14/21 TD Securities
Shopify initiated with a Hold at TD Securities
09/29/21 Baird
Shopify price target lowered to $1650 from $1700 at Baird
09/10/21 BofA
Affirm price target raised to $119 from $82 at BofA
CAT Caterpillar
$196.10 /

-3.53 (-1.77%)

10/14/21
Fly Intel: Top five analyst initiations
10/14/21 Evercore ISI
Caterpillar price target lowered to $257 from $291 at Evercore ISI
10/14/21 Cowen
Cowen starts Caterpillar at Outperform into 'first megacycle' in 14 years
10/14/21 Cowen
Caterpillar initiated with an Outperform at Cowen
BUD AB InBev
$57.18 /

+0.275 (+0.48%)

10/19/21 Jefferies
Altria move for control of Juul 'even more likely and necessary,' says Jefferies
10/14/21 Morgan Stanley
Odds rising of Altria monetizing AB InBev stake, says Morgan Stanley
10/08/21 Morgan Stanley
AB InBev price target lowered to EUR 53 from EUR 57 at Morgan Stanley
10/07/21 UBS
AB InBev price target lowered to EUR 51 from EUR 63 at UBS
MO Altria Group
$47.49 /

-0.625 (-1.30%)

10/19/21 Jefferies
Altria move for control of Juul 'even more likely and necessary,' says Jefferies
10/14/21 Morgan Stanley
Odds rising of Altria monetizing AB InBev stake, says Morgan Stanley
09/30/21 Stifel
Stifel surprised and 'disappointed' by ITC banning IQOS importation
09/30/21 BofA
Altria, Philip Morris still well positioned despite IQOS 'setback,' says BofA
KDP Keurig Dr Pepper
$34.20 /

-0.37 (-1.07%)

10/04/21 JPMorgan
Keurig Dr Pepper should be bought on weakness, says JPMorgan
09/20/21 Deutsche Bank
Keurig Dr Pepper price target raised to $36 from $35 at Deutsche Bank
06/29/21
Fly Intel: Top five analyst upgrades
06/29/21 Wells Fargo
Wells Fargo upgrades Keurig Dr Pepper on carbonated beverage tailwind
YUM Yum! Brands
$125.88 /

-0.43 (-0.34%)

10/05/21 Loop Capital
Yum! Brands initiated with a Hold at Loop Capital
08/26/21
Fly Intel: Top five analyst downgrades
08/26/21 Oppenheimer
Yum! Brands downgraded to Perform at Oppenheimer
08/26/21 Oppenheimer
Restaurant Brands upgraded to Outperform at Oppenheimer
HSY Hershey
$179.48 /

-2.48 (-1.36%)

10/18/21 Deutsche Bank
Hershey price target raised to $184 from $174 at Deutsche Bank
10/04/21 Goldman Sachs
Hershey price target raised to $191 from $190 at Goldman Sachs
09/21/21 Morgan Stanley
Hershey assumed with an Equal Weight at Morgan Stanley
07/30/21 BMO Capital
Hershey price target raised to $181 from $175 at BMO Capital
SWK Stanley Black & Decker
$186.30 /

-0.375 (-0.20%)

10/07/21 Wells Fargo
Wells starts Stanley Black & Decker at Overweight on favorable setup
10/07/21 Wells Fargo
Stanley Black & Decker initiated with an Overweight at Wells Fargo
07/14/21 Deutsche Bank
Stanley Black & Decker price target lowered to $238 from $241 at Deutsche Bank
06/17/21
Fly Intel: Top five analyst upgrades
SIRI Sirius XM
$5.97 /

-0.08 (-1.32%)

10/19/21 Pivotal Research
Sirius XM price target lowered to $8 from $8.25 at Pivotal Research
10/08/21
Fly Intel: Top five analyst downgrades
10/08/21 JPMorgan
JPMorgan downgrades Sirius XM on slowing car sales, higher costs
10/08/21 JPMorgan
Sirius XM downgraded to Neutral from Overweight at JPMorgan
HBAN Huntington Bancshares
$15.98 /

-0.5 (-3.03%)

09/07/21 Baird
Huntington Bancshares weakness a buying opportunity, says Baird
08/18/21 Goldman Sachs
Huntington Bancshares reinstated with a Buy at Goldman Sachs
07/06/21 Keefe Bruyette
Huntington Bancshares assumed with a Market Perform at Keefe Bruyette
06/23/21 Raymond James
Huntington Bancshares upgraded to Strong Buy from Outperform at Raymond James
TAP Molson Coors
$43.66 /

+0.105 (+0.24%)

10/20/21 Alliance Global Partners
Alliance Global Partners cuts Hexo target to C$5 following executive changes
10/18/21 Deutsche Bank
Molson Coors price target lowered to $48 from $50 at Deutsche Bank
09/16/21 Barclays
Molson Coors price target lowered to $48 from $53 at Barclays
06/21/21 Guggenheim
Boston Beer named a 'Best Idea' at Guggenheim
TPX Tempur Sealy
$46.74 /

-0.88 (-1.85%)

07/30/21 Wedbush
Tempur Sealy price target raised to $53 from $45 at Wedbush
04/30/21 Truist
Tempur Sealy price target raised to $50 from $45 at Truist
04/30/21 Piper Sandler
Tempur Sealy share weakness a buying opportunity, says Piper Sandler
04/12/21 UBS
Tempur Sealy price target raised to $48 from $40 at UBS
NLSN Nielsen
$19.42 /

+0.005 (+0.03%)

09/10/21 Citi
Nielsen price target lowered to $21 from $28 at Citi
08/25/21 Craig-Hallum
Comscore accreditation audit process accelerated, says Craig-Hallum
07/07/21 RBC Capital
Nielsen initiated with a Sector Perform at RBC Capital
06/28/21 Craig-Hallum
Craig-Hallum bullish on Comscore, initiates with a Buy
MA MasterCard
$335.50 /

-21.81 (-6.10%)

CMCSA Comcast
$52.46 /

-1.29 (-2.40%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

MRK Merck
$81.53 /

-0.7 (-0.85%)

SHOP Shopify
$1,361.52 /

-2.59 (-0.19%)

CAT Caterpillar
$196.10 /

-3.53 (-1.77%)

BUD AB InBev
$57.18 /

+0.275 (+0.48%)

MO Altria Group
$47.49 /

-0.625 (-1.30%)

KDP Keurig Dr Pepper
$34.20 /

-0.37 (-1.07%)

YUM Yum! Brands
$125.88 /

-0.43 (-0.34%)

HSY Hershey
$179.48 /

-2.48 (-1.36%)

SWK Stanley Black & Decker
$186.30 /

-0.375 (-0.20%)

SIRI Sirius XM
$5.97 /

-0.08 (-1.32%)

HBAN Huntington Bancshares
$15.98 /

-0.5 (-3.03%)

TAP Molson Coors
$43.66 /

+0.105 (+0.24%)

TPX Tempur Sealy
$46.74 /

-0.88 (-1.85%)

NLSN Nielsen
$19.42 /

+0.005 (+0.03%)

  • 08
    Jun
  • 23
    Feb
  • 17
    Nov
MA MasterCard
$335.50 /

-21.81 (-6.10%)

CMCSA Comcast
$52.46 /

-1.29 (-2.40%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

MRK Merck
$81.53 /

-0.7 (-0.85%)

SHOP Shopify
$1,361.52 /

-2.59 (-0.19%)

CAT Caterpillar
$196.10 /

-3.53 (-1.77%)

BUD AB InBev
$57.18 /

+0.275 (+0.48%)

MO Altria Group
$47.49 /

-0.625 (-1.30%)

YUM Yum! Brands
$125.88 /

-0.43 (-0.34%)

SWK Stanley Black & Decker
$186.30 /

-0.375 (-0.20%)

NLSN Nielsen
$19.42 /

+0.005 (+0.03%)

MA MasterCard
$335.50 /

-21.81 (-6.10%)

CMCSA Comcast
$52.46 /

-1.29 (-2.40%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

MRK Merck
$81.53 /

-0.7 (-0.85%)

SHOP Shopify
$1,361.52 /

-2.59 (-0.19%)

CAT Caterpillar
$196.10 /

-3.53 (-1.77%)

BUD AB InBev
$57.18 /

+0.275 (+0.48%)

MO Altria Group
$47.49 /

-0.625 (-1.30%)

KDP Keurig Dr Pepper
$34.20 /

-0.37 (-1.07%)

YUM Yum! Brands
$125.88 /

-0.43 (-0.34%)

HSY Hershey
$179.48 /

-2.48 (-1.36%)

SWK Stanley Black & Decker
$186.30 /

-0.375 (-0.20%)

SIRI Sirius XM
$5.97 /

-0.08 (-1.32%)

HBAN Huntington Bancshares
$15.98 /

-0.5 (-3.03%)

TAP Molson Coors
$43.66 /

+0.105 (+0.24%)

TPX Tempur Sealy
$46.74 /

-0.88 (-1.85%)

MA MasterCard
$335.50 /

-21.81 (-6.10%)

CMCSA Comcast
$52.46 /

-1.29 (-2.40%)

MRK Merck
$81.53 /

-0.7 (-0.85%)

SHOP Shopify
$1,361.52 /

-2.59 (-0.19%)

CAT Caterpillar
$196.10 /

-3.53 (-1.77%)

BUD AB InBev
$57.18 /

+0.275 (+0.48%)

MO Altria Group
$47.49 /

-0.625 (-1.30%)

KDP Keurig Dr Pepper
$34.20 /

-0.37 (-1.07%)

YUM Yum! Brands
$125.88 /

-0.43 (-0.34%)

SIRI Sirius XM
$5.97 /

-0.08 (-1.32%)

TAP Molson Coors
$43.66 /

+0.105 (+0.24%)

Earnings
Notable companies reporting before tomorrow's open » 13:55
10/27/21
10/27
13:55
10/27/21
13:55
MA

MasterCard

$336.05 /

-21.26 (-5.95%)

, CMCSA

Comcast

$52.76 /

-0.99 (-1.84%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

, MRK

Merck

$81.78 /

-0.45 (-0.55%)

, SHOP

Shopify

$1,351.76 /

-12.35 (-0.91%)

, CAT

Caterpillar

$196.99 /

-2.64 (-1.32%)

, BUD

AB InBev

$57.24 /

+0.335 (+0.59%)

, MO

Altria Group

$47.43 /

-0.685 (-1.42%)

, KDP

Keurig Dr Pepper

$34.31 /

-0.26 (-0.75%)

, YUM

Yum! Brands

$126.53 /

+0.22 (+0.17%)

, HSY

Hershey

$179.38 /

-2.58 (-1.42%)

, SWK

Stanley Black & Decker

$188.10 /

+1.425 (+0.76%)

, SIRI

Sirius XM

$6.03 /

-0.02 (-0.33%)

, HBAN

Huntington Bancshares

$16.09 /

-0.39 (-2.37%)

, TAP

Molson Coors

$43.33 /

-0.225 (-0.52%)

, TPX

Tempur Sealy

$46.72 /

-0.9 (-1.89%)

, NLSN

Nielsen

$19.51 /

+0.1 (+0.52%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include MasterCard (MA), consensus $2.19c... Comcast (CMCSA), consensus 75c... Merck (MRK), consensus $1.55... Shopify (SHOP), consensus $1.32... Caterpillar (CAT), consensus $2.20... AB InBev (BUD), consensus 66c... Altria Group (MO), consensus $1.26... Keurig Dr Pepper (KDP), consensus 44c... Yum! Brands (YUM), consensus $1.08... Hershey (HSY), consensus $2... Stanley Black & Decker (SWK), consensus $2.47... Sirius XM (SIRI), consensus 7c... Huntington Bancshares (HBAN), consensus 32c... Molson Coors (TAP), consensus $1.53... Tempur Sealy (TPX), consensus 84c... Nielsen (NLSN), consensus 36c.

ShowHide Related Items >><<
YUM Yum! Brands
$126.53 /

+0.22 (+0.17%)

TPX Tempur Sealy
$46.72 /

-0.9 (-1.89%)

TAP Molson Coors
$43.33 /

-0.225 (-0.52%)

SWK Stanley Black & Decker
$188.10 /

+1.425 (+0.76%)

SIRI Sirius XM
$6.03 /

-0.02 (-0.33%)

SHOP Shopify
$1,351.76 /

-12.35 (-0.91%)

NLSN Nielsen
$19.51 /

+0.1 (+0.52%)

MRK Merck
$81.78 /

-0.45 (-0.55%)

MO Altria Group
$47.43 /

-0.685 (-1.42%)

MA MasterCard
$336.05 /

-21.26 (-5.95%)

KDP Keurig Dr Pepper
$34.31 /

-0.26 (-0.75%)

HSY Hershey
$179.38 /

-2.58 (-1.42%)

HBAN Huntington Bancshares
$16.09 /

-0.39 (-2.37%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$52.76 /

-0.99 (-1.84%)

CAT Caterpillar
$196.99 /

-2.64 (-1.32%)

BUD AB InBev
$57.24 /

+0.335 (+0.59%)

MA MasterCard
$336.05 /

-21.26 (-5.95%)

09/29/21 Stephens
Affirm's long-term economic expectations weaker than forecast, says Stephens
09/03/21 Deutsche Bank
Deutsche says many concerns over Visa and MasterCard are minor
08/17/21 JPMorgan
MasterCard price target raised to $430 from $427 at JPMorgan
08/12/21 Daiwa
MasterCard downgraded to Neutral from Outperform at Daiwa
CMCSA Comcast
$52.76 /

-0.99 (-1.84%)

10/13/21 Morgan Stanley
Morgan Stanley says Comcast dropping network a modest near-term negative for MSG
10/12/21 Deutsche Bank
Comcast price target lowered to $64 from $68 at Deutsche Bank
10/11/21
Fly Intel: Top five analyst downgrades
10/11/21 Raymond James
Comcast downgraded to Market Perform from Outperform at Raymond James
CMCSK Comcast
$58.00 /

+ (+0.00%)

02/23/21 Credit Suisse
SeaWorld price target raised to $52 from $34 at Credit Suisse
MRK Merck
$81.78 /

-0.45 (-0.55%)

10/22/21 SVB Leerink
Merck price target raised to $105 from $104 at SVB Leerink
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/19/21 Evercore ISI
Atea's Phase 2 design disappoints, but drug has not failed, says Evercore ISI
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
SHOP Shopify
$1,351.76 /

-12.35 (-0.91%)

10/14/21 TD Securities
TD Securities starts Shopify with Hold, says opportunities seem priced in
10/14/21 TD Securities
Shopify initiated with a Hold at TD Securities
09/29/21 Baird
Shopify price target lowered to $1650 from $1700 at Baird
09/10/21 BofA
Affirm price target raised to $119 from $82 at BofA
CAT Caterpillar
$196.99 /

-2.64 (-1.32%)

10/14/21
Fly Intel: Top five analyst initiations
10/14/21 Evercore ISI
Caterpillar price target lowered to $257 from $291 at Evercore ISI
10/14/21 Cowen
Cowen starts Caterpillar at Outperform into 'first megacycle' in 14 years
10/14/21 Cowen
Caterpillar initiated with an Outperform at Cowen
BUD AB InBev
$57.24 /

+0.335 (+0.59%)

10/19/21 Jefferies
Altria move for control of Juul 'even more likely and necessary,' says Jefferies
10/14/21 Morgan Stanley
Odds rising of Altria monetizing AB InBev stake, says Morgan Stanley
10/08/21 Morgan Stanley
AB InBev price target lowered to EUR 53 from EUR 57 at Morgan Stanley
10/07/21 UBS
AB InBev price target lowered to EUR 51 from EUR 63 at UBS
MO Altria Group
$47.43 /

-0.685 (-1.42%)

09/30/21 Stifel
Stifel surprised and 'disappointed' by ITC banning IQOS importation
09/30/21 BofA
Altria, Philip Morris still well positioned despite IQOS 'setback,' says BofA
KDP Keurig Dr Pepper
$34.31 /

-0.26 (-0.75%)

10/04/21 JPMorgan
Keurig Dr Pepper should be bought on weakness, says JPMorgan
09/20/21 Deutsche Bank
Keurig Dr Pepper price target raised to $36 from $35 at Deutsche Bank
06/29/21
Fly Intel: Top five analyst upgrades
06/29/21 Wells Fargo
Wells Fargo upgrades Keurig Dr Pepper on carbonated beverage tailwind
YUM Yum! Brands
$126.53 /

+0.22 (+0.17%)

10/05/21 Loop Capital
Yum! Brands initiated with a Hold at Loop Capital
08/26/21
Fly Intel: Top five analyst downgrades
08/26/21 Oppenheimer
Yum! Brands downgraded to Perform at Oppenheimer
08/26/21 Oppenheimer
Restaurant Brands upgraded to Outperform at Oppenheimer
HSY Hershey
$179.38 /

-2.58 (-1.42%)

10/18/21 Deutsche Bank
Hershey price target raised to $184 from $174 at Deutsche Bank
10/04/21 Goldman Sachs
Hershey price target raised to $191 from $190 at Goldman Sachs
09/21/21 Morgan Stanley
Hershey assumed with an Equal Weight at Morgan Stanley
07/30/21 BMO Capital
Hershey price target raised to $181 from $175 at BMO Capital
SWK Stanley Black & Decker
$188.10 /

+1.425 (+0.76%)

10/07/21 Wells Fargo
Wells starts Stanley Black & Decker at Overweight on favorable setup
10/07/21 Wells Fargo
Stanley Black & Decker initiated with an Overweight at Wells Fargo
07/14/21 Deutsche Bank
Stanley Black & Decker price target lowered to $238 from $241 at Deutsche Bank
06/17/21
Fly Intel: Top five analyst upgrades
SIRI Sirius XM
$6.03 /

-0.02 (-0.33%)

10/19/21 Pivotal Research
Sirius XM price target lowered to $8 from $8.25 at Pivotal Research
10/08/21
Fly Intel: Top five analyst downgrades
10/08/21 JPMorgan
JPMorgan downgrades Sirius XM on slowing car sales, higher costs
10/08/21 JPMorgan
Sirius XM downgraded to Neutral from Overweight at JPMorgan
HBAN Huntington Bancshares
$16.09 /

-0.39 (-2.37%)

09/07/21 Baird
Huntington Bancshares weakness a buying opportunity, says Baird
08/18/21 Goldman Sachs
Huntington Bancshares reinstated with a Buy at Goldman Sachs
07/06/21 Keefe Bruyette
Huntington Bancshares assumed with a Market Perform at Keefe Bruyette
06/23/21 Raymond James
Huntington Bancshares upgraded to Strong Buy from Outperform at Raymond James
TAP Molson Coors
$43.33 /

-0.225 (-0.52%)

10/20/21 Alliance Global Partners
Alliance Global Partners cuts Hexo target to C$5 following executive changes
10/18/21 Deutsche Bank
Molson Coors price target lowered to $48 from $50 at Deutsche Bank
09/16/21 Barclays
Molson Coors price target lowered to $48 from $53 at Barclays
06/21/21 Guggenheim
Boston Beer named a 'Best Idea' at Guggenheim
TPX Tempur Sealy
$46.72 /

-0.9 (-1.89%)

07/30/21 Wedbush
Tempur Sealy price target raised to $53 from $45 at Wedbush
04/30/21 Truist
Tempur Sealy price target raised to $50 from $45 at Truist
04/30/21 Piper Sandler
Tempur Sealy share weakness a buying opportunity, says Piper Sandler
04/12/21 UBS
Tempur Sealy price target raised to $48 from $40 at UBS
NLSN Nielsen
$19.51 /

+0.1 (+0.52%)

09/10/21 Citi
Nielsen price target lowered to $21 from $28 at Citi
08/25/21 Craig-Hallum
Comscore accreditation audit process accelerated, says Craig-Hallum
07/07/21 RBC Capital
Nielsen initiated with a Sector Perform at RBC Capital
06/28/21 Craig-Hallum
Craig-Hallum bullish on Comscore, initiates with a Buy
YUM Yum! Brands
$126.53 /

+0.22 (+0.17%)

TPX Tempur Sealy
$46.72 /

-0.9 (-1.89%)

TAP Molson Coors
$43.33 /

-0.225 (-0.52%)

SWK Stanley Black & Decker
$188.10 /

+1.425 (+0.76%)

SIRI Sirius XM
$6.03 /

-0.02 (-0.33%)

SHOP Shopify
$1,351.76 /

-12.35 (-0.91%)

NLSN Nielsen
$19.51 /

+0.1 (+0.52%)

MRK Merck
$81.78 /

-0.45 (-0.55%)

MO Altria Group
$47.43 /

-0.685 (-1.42%)

MA MasterCard
$336.05 /

-21.26 (-5.95%)

KDP Keurig Dr Pepper
$34.31 /

-0.26 (-0.75%)

HSY Hershey
$179.38 /

-2.58 (-1.42%)

HBAN Huntington Bancshares
$16.09 /

-0.39 (-2.37%)

CMCSA Comcast
$52.76 /

-0.99 (-1.84%)

CAT Caterpillar
$196.99 /

-2.64 (-1.32%)

BUD AB InBev
$57.24 /

+0.335 (+0.59%)

  • 08
    Jun
  • 23
    Feb
  • 17
    Nov
YUM Yum! Brands
$126.53 /

+0.22 (+0.17%)

SWK Stanley Black & Decker
$188.10 /

+1.425 (+0.76%)

SHOP Shopify
$1,351.76 /

-12.35 (-0.91%)

NLSN Nielsen
$19.51 /

+0.1 (+0.52%)

MRK Merck
$81.78 /

-0.45 (-0.55%)

MO Altria Group
$47.43 /

-0.685 (-1.42%)

MA MasterCard
$336.05 /

-21.26 (-5.95%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$52.76 /

-0.99 (-1.84%)

CAT Caterpillar
$196.99 /

-2.64 (-1.32%)

BUD AB InBev
$57.24 /

+0.335 (+0.59%)

YUM Yum! Brands
$126.53 /

+0.22 (+0.17%)

TPX Tempur Sealy
$46.72 /

-0.9 (-1.89%)

TAP Molson Coors
$43.33 /

-0.225 (-0.52%)

SWK Stanley Black & Decker
$188.10 /

+1.425 (+0.76%)

SIRI Sirius XM
$6.03 /

-0.02 (-0.33%)

SHOP Shopify
$1,351.76 /

-12.35 (-0.91%)

MRK Merck
$81.78 /

-0.45 (-0.55%)

MO Altria Group
$47.43 /

-0.685 (-1.42%)

MA MasterCard
$336.05 /

-21.26 (-5.95%)

KDP Keurig Dr Pepper
$34.31 /

-0.26 (-0.75%)

HSY Hershey
$179.38 /

-2.58 (-1.42%)

HBAN Huntington Bancshares
$16.09 /

-0.39 (-2.37%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$52.76 /

-0.99 (-1.84%)

CAT Caterpillar
$196.99 /

-2.64 (-1.32%)

BUD AB InBev
$57.24 /

+0.335 (+0.59%)

YUM Yum! Brands
$126.53 /

+0.22 (+0.17%)

TAP Molson Coors
$43.33 /

-0.225 (-0.52%)

SIRI Sirius XM
$6.03 /

-0.02 (-0.33%)

SHOP Shopify
$1,351.76 /

-12.35 (-0.91%)

MRK Merck
$81.78 /

-0.45 (-0.55%)

MO Altria Group
$47.43 /

-0.685 (-1.42%)

MA MasterCard
$336.05 /

-21.26 (-5.95%)

CMCSA Comcast
$52.76 /

-0.99 (-1.84%)

CAT Caterpillar
$196.99 /

-2.64 (-1.32%)

BUD AB InBev
$57.24 /

+0.335 (+0.59%)

Earnings
Acceleron expects Q3 royalty revenue of approximately $32M from Reblozy » 07:16
10/27/21
10/27
07:16
10/27/21
07:16
XLRN

Acceleron

$173.85 /

+0.23 (+0.13%)

, BMY

Bristol-Myers

$58.24 /

+0.47 (+0.81%)

Acceleron Pharma (XLRN) …

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XLRN Acceleron
$173.85 /

+0.23 (+0.13%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

XLRN Acceleron
$173.85 /

+0.23 (+0.13%)

10/06/21 Jefferies
Acceleron initiated with a Hold at Jefferies
10/04/21 Raymond James
Acceleron downgraded to Market Perform from Strong Buy at Raymond James
10/01/21 Barclays
Acceleron downgraded to Equal Weight from Overweight at Barclays
09/30/21 Cowen
Acceleron downgraded to Market Perform from Outperform at Cowen
BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

10/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $34 from $23 at RBC Capital
10/25/21 SVB Leerink
Potential Bristol takeover of Aurinia makes strategic sense, says SVB Leerink
10/25/21 Citi
Bristol-Myers report of Aurinia approach 'looks credible,' says Citi
10/12/21 Morgan Stanley
Bristol-Myers price target lowered to $66 from $71 at Morgan Stanley
XLRN Acceleron
$173.85 /

+0.23 (+0.13%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

XLRN Acceleron
$173.85 /

+0.23 (+0.13%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

XLRN Acceleron
$173.85 /

+0.23 (+0.13%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

Hot Stocks
Merck says islatravir/doravirine combo maintained viral suppression at week 144 » 06:48
10/27/21
10/27
06:48
10/27/21
06:48
MRK

Merck

$82.23 /

+0.545 (+0.67%)

Merck announced Week 144…

Merck announced Week 144 data from the Phase 2b dose-ranging study evaluating the antiretroviral activity, tolerability, and safety of islatravir in combination with doravirine compared to doravirine/lamivudine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults with HIV-1. Phase 2b data through 144 weeks demonstrated that islatravir combined with doravirine continued to maintain viral suppression, as measured by the number of study participants achieving HIV-1 RNA levels less than50 copies/mL, similar to DOR/3TC/TDF. The data further characterized the tolerability and safety profile of islatravir in combination with doravirine. The Week 144 results are a follow-up to the Week 96 results and safety data presented at the virtual 2020 International Congress on Drug Therapy in HIV Infection, or HIV Glasgow 2020, and the virtual International AIDS Society Conference on HIV Science, or IAS 2021, respectively. The Week 144 data were consistent with the Week 96 results in the 0.75 mg dose group, the selected Phase 3 dose, and were shared as an oral presentation during the 18th European AIDS Conference, or EACS 2021, the company noted. Islatravir is currently being evaluated across a variety of dosing regimens, for both the treatment of HIV-1 in combination with other antiretroviral agents and for the prevention of HIV-1 as a monotherapy. "We are encouraged by the Week 144 findings presented at EACS, which further support the potential of a two-drug doravirine/islatravir regimen for the treatment of HIV-1. As we advance the ILLUMINATE clinical development program, we look forward to continuing to study this investigational treatment across diverse patient populations," said Dr. Joan Butterton, vice president, global clinical development, infectious diseases, Merck Research Laboratories.

ShowHide Related Items >><<
MRK Merck
$82.23 /

+0.545 (+0.67%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

10/22/21 SVB Leerink
Merck price target raised to $105 from $104 at SVB Leerink
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/19/21 Evercore ISI
Atea's Phase 2 design disappoints, but drug has not failed, says Evercore ISI
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
MRK Merck
$82.23 /

+0.545 (+0.67%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

Hot Stocks
Merck, MPP enter license agreement for molnupiravir » 06:03
10/27/21
10/27
06:03
10/27/21
06:03
MRK

Merck

$82.23 /

+0.545 (+0.67%)

The Medicines Patent Pool…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$82.23 /

+0.545 (+0.67%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

10/22/21 SVB Leerink
Merck price target raised to $105 from $104 at SVB Leerink
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/19/21 Evercore ISI
Atea's Phase 2 design disappoints, but drug has not failed, says Evercore ISI
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
MRK Merck
$82.23 /

+0.545 (+0.67%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

Conference/Events
American Society for Radiation Oncology to hold annual meeting » 04:55
10/27/21
10/27
04:55
10/27/21
04:55
ARAY

Accuray

$4.31 /

-0.08 (-1.82%)

, NVS

Novartis

$84.84 /

+1.49 (+1.79%)

, AZN

AstraZeneca

$62.29 /

+0.54 (+0.87%)

, BAYRY

Bayer

$14.20 /

+0.04 (+0.28%)

, BD

Budget Group

/

+

, BIOC

Biocept

$3.76 /

-0.08 (-2.08%)

, BSX

Boston Scientific

$44.32 /

-0.17 (-0.38%)

, BMY

Bristol-Myers

$58.24 /

+0.47 (+0.81%)

, EKTAY

Elekta

$11.58 /

+0.09 (+0.78%)

, GRTX

Galera Therapeutics

$1.88 /

+0.04 (+2.17%)

, DNA

Ginkgo Bioworks

$14.46 /

+0.19 (+1.33%)

, HTHIY

Hitachi

$118.77 /

-0.71 (-0.59%)

, MRK

Merck

$82.23 /

+0.545 (+0.67%)

, MYGN

Myriad Genetics

$30.66 /

-1.81 (-5.57%)

, NBTX

Nanobiotix

$12.35 /

-0.3 (-2.37%)

, NNOX

Nano-X Imaging

$22.54 /

-0.55 (-2.38%)

, NTRA

Natera

$115.95 /

+0.2 (+0.17%)

, NVCR

Novocure

$113.51 /

-5.91 (-4.95%)

, PHG

Philips

$47.69 /

-0.12 (-0.25%)

, REGN

Regeneron

$592.37 /

+16.45 (+2.86%)

, SNY

Sanofi

$49.98 /

+0.125 (+0.25%)

, SGEN

Seagen

$177.70 /

+2.29 (+1.31%)

, SMMNY

Siemens Healthineers

$34.66 /

-0.07 (-0.20%)

, SYK

Stryker

$273.25 /

+0.08 (+0.03%)

, TDY

Teledyne

$437.11 /

-7.89 (-1.77%)

, VRAY

ViewRay

$6.96 /

-0.05 (-0.71%)

, VREX

Varex Imaging

$26.36 /

-0.7 (-2.59%)

63rd Annual ASTRO Meeting…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VRAY ViewRay
$6.96 /

-0.05 (-0.71%)

TDY Teledyne
$437.11 /

-7.89 (-1.77%)

SYK Stryker
$273.25 /

+0.08 (+0.03%)

SNY Sanofi
$49.98 /

+0.125 (+0.25%)

SMMNY Siemens Healthineers
$34.66 /

-0.07 (-0.20%)

SGEN Seagen
$177.70 /

+2.29 (+1.31%)

REGN Regeneron
$592.37 /

+16.45 (+2.86%)

PHG Philips
$47.69 /

-0.12 (-0.25%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

NVCR Novocure
$113.51 /

-5.91 (-4.95%)

NTRA Natera
$115.95 /

+0.2 (+0.17%)

NNOX Nano-X Imaging
$22.54 /

-0.55 (-2.38%)

NBTX Nanobiotix
$12.35 /

-0.3 (-2.37%)

MYGN Myriad Genetics
$30.66 /

-1.81 (-5.57%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

HTHIY Hitachi
$118.77 /

-0.71 (-0.59%)

GRTX Galera Therapeutics
$1.88 /

+0.04 (+2.17%)

EKTAY Elekta
$11.58 /

+0.09 (+0.78%)

DNA Ginkgo Bioworks
$14.46 /

+0.19 (+1.33%)

BSX Boston Scientific
$44.32 /

-0.17 (-0.38%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BIOC Biocept
$3.76 /

-0.08 (-2.08%)

BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

ARAY Accuray
$4.31 /

-0.08 (-1.82%)

ARAY Accuray
$4.31 /

-0.08 (-1.82%)

10/26/21 Lake Street
Investors should buy Accuray after 'excellent' ASTRO meeting, says Lake Street
01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Northland
Accuray initiated with an Outperform at Northland
NVS Novartis
$84.84 /

+1.49 (+1.79%)

10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
10/08/21 UBS
Novartis price target lowered to CHF 92 from CHF 95 at UBS
09/29/21 Stifel
Blueprint Medicines rersumed with a Hold at Stifel
09/20/21 Deutsche Bank
Novartis downgraded to Sell from Hold at Deutsche Bank
AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
10/11/21 Deutsche Bank
AstraZeneca price target raised to 10,500 GBp from 10,200 GBp at Deutsche Bank
09/29/21 Stifel
Zentalis initiated with a Buy at Stifel
09/29/21 H.C. Wainwright
H.C. Wainwright says Astra deal for Caelum to yield 'nice check' for Fortress
BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

10/21/21 Morgan Stanley
Bayer price target raised to EUR 71 from EUR 70 at Morgan Stanley
08/09/21 Berenberg
Bayer price target lowered to EUR 60 from EUR 74 at Berenberg
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
BD Budget Group
/

+

BIOC Biocept
$3.76 /

-0.08 (-2.08%)

10/08/21 Brookline
Biocept assumed with a Buy at Brookline
BSX Boston Scientific
$44.32 /

-0.17 (-0.38%)

10/06/21 Piper Sandler
Boston Scientific acquisition of Baylis looks 'solid,' says Piper Sandler
09/22/21 Piper Sandler
Boston Scientific said unlikely to hit low end of Q3 sales outlook, notes Piper
09/14/21 Piper Sandler
CMS full repeal proposal of MCIT negative for med tech, says Piper Sandler
08/31/21 BTIG
Abbott price target raised to $136 from $126 at BTIG
BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

10/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $34 from $23 at RBC Capital
10/25/21 SVB Leerink
Potential Bristol takeover of Aurinia makes strategic sense, says SVB Leerink
10/25/21 Citi
Bristol-Myers report of Aurinia approach 'looks credible,' says Citi
10/12/21 Morgan Stanley
Bristol-Myers price target lowered to $66 from $71 at Morgan Stanley
EKTAY Elekta
$11.58 /

+0.09 (+0.78%)

08/27/21 JPMorgan
Elekta price target raised to SEK 95 from SEK 91 at JPMorgan
06/02/21 JPMorgan
Elekta price target raised to SEK 91 from SEK 82 at JPMorgan
04/27/21 JPMorgan
Elekta price target raised to SEK 82 from SEK 80 at JPMorgan
03/18/21 JPMorgan
Elekta downgraded to Underweight from Neutral at JPMorgan
GRTX Galera Therapeutics
$1.88 /

+0.04 (+2.17%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
DNA Ginkgo Bioworks
$14.46 /

+0.19 (+1.33%)

10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
10/13/21 Raymond James
Ginkgo Bioworks initiated with an Outperform at Raymond James
10/12/21 William Blair
Blair starts Ginkgo at Outperform on 'significant' competitive advantage
10/12/21 William Blair
Ginkgo Bioworks initiated with an Outperform at William Blair
HTHIY Hitachi
$118.77 /

-0.71 (-0.59%)

11/20/20 Goldman Sachs
Hitachi reinstated with a Sell at Goldman Sachs
MRK Merck
$82.23 /

+0.545 (+0.67%)

10/22/21 SVB Leerink
Merck price target raised to $105 from $104 at SVB Leerink
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/19/21 Evercore ISI
Atea's Phase 2 design disappoints, but drug has not failed, says Evercore ISI
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
MYGN Myriad Genetics
$30.66 /

-1.81 (-5.57%)

10/14/21 Cowen
Myriad Genetics coverage transferred at Cowen
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Myriad Genetics initiated with a Market Perform at Raymond James
06/03/21 Goldman Sachs
Myriad Genetics initiated with a Sell at Goldman Sachs
NBTX Nanobiotix
$12.35 /

-0.3 (-2.37%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
NNOX Nano-X Imaging
$22.54 /

-0.55 (-2.38%)

04/19/21 Ladenburg
Ladenburg starts Nano-X Imaging at Buy with $52 price target
04/19/21 Ladenburg
Nano-X Imaging initiated with a Buy at Ladenburg
02/01/21 Cantor Fitzgerald
Cantor Fitzgerald reiterates Overweight on Nano-X Imaging, lowers target to $67
NTRA Natera
$115.95 /

+0.2 (+0.17%)

10/19/21 Canaccord
Natera Prospera Lung launch to continue momentum, says Canaccord
10/14/21 Cowen
Natera coverage transferred at Cowen
08/31/21 Craig-Hallum
Natera seeks to challenge CareDx franchise with launch, says Craig-Hallum
08/09/21 Piper Sandler
Natera price target raised to $160 from $155 at Piper Sandler
NVCR Novocure
$113.51 /

-5.91 (-4.95%)

10/25/21 Piper Sandler
Novocure price target lowered to $195 from $235 at Piper Sandler
09/21/21 Piper Sandler
Novocure clinical update should come in next few weeks, says Piper Sandler
07/30/21 Mizuho
Novocure price target lowered to $200 from $229 at Mizuho
PHG Philips
$47.69 /

-0.12 (-0.25%)

10/25/21 Credit Suisse
Philips price target lowered to EUR 42 from EUR 49 at Credit Suisse
10/19/21 JPMorgan
Philips price target lowered to EUR 36.40 from EUR 40.90 at JPMorgan
10/19/21 Deutsche Bank
Philips price target lowered to EUR 42 from EUR 43 at Deutsche Bank
09/10/21 Barclays
Philips price target lowered to EUR 53 from EUR 54 at Barclays
REGN Regeneron
$592.37 /

+16.45 (+2.86%)

10/26/21 SVB Leerink
Regeneron price target raised to $798 from $785 at SVB Leerink
10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/22/21 H.C. Wainwright
Regeneron price target raised to $842 from $831 at H.C. Wainwright
10/14/21 H.C. Wainwright
H.C. Wainwright 'enthusiastic' on Regeneron, sees no barrier for REGEN-COV nod
SNY Sanofi
$49.98 /

+0.125 (+0.25%)

10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
09/27/21 SVB Leerink
Sanofi upgraded to Outperform from Market Perform at SVB Leerink
SGEN Seagen
$177.70 /

+2.29 (+1.31%)

10/14/21 BTIG
Seagen assumed with a Neutral at BTIG
09/27/21 RBC Capital
Seagen price target raised to $154 from $148 at RBC Capital
05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
SMMNY Siemens Healthineers
$34.66 /

-0.07 (-0.20%)

10/13/21 UBS
Siemens Healthineers price target raised to EUR 54 from EUR 48 at UBS
10/01/21 Societe Generale
Siemens Healthineers downgraded to Hold at Societe Generale
10/01/21 Societe Generale
Siemens Healthineers downgraded to Hold from Buy at Societe Generale
09/10/21 Barclays
Siemens Healthineers price target raised to EUR 55 from EUR 49 at Barclays
SYK Stryker
$273.25 /

+0.08 (+0.03%)

09/14/21 Raymond James
Stryker resumed with a Market Perform at Raymond James
07/29/21 Argus
Stryker price target raised to $320 from $280 at Argus
07/28/21
Fly Intel: Top five analyst upgrades
07/28/21 SVB Leerink
Stryker price target raised to $300 from $290 at SVB Leerink
TDY Teledyne
$437.11 /

-7.89 (-1.77%)

07/30/21 Cowen
Teledyne price target raised to $525 from $500 at Cowen
06/08/21 Goldman Sachs
Teledyne reinstated with a Neutral at Goldman Sachs
05/25/21 BofA
Teledyne initiated with a Buy at BofA
04/29/21 Needham
Teledyne price target raised to $500 from $416 at Needham
VRAY ViewRay
$6.96 /

-0.05 (-0.71%)

10/19/21 Piper Sandler
ViewRay strength attributed to MIRAGE study recruiting halt, says Piper Sandler
10/14/21 B. Riley
ViewRay resumed with a Neutral at B. Riley
10/14/21 B. Riley
ViewRay resumed with a Neutral at B. Riley
06/25/21 Morgan Stanley
ViewRay upgraded to Equal Weight from Underweight at Morgan Stanley
VREX Varex Imaging
$26.36 /

-0.7 (-2.59%)

02/05/21 Oppenheimer
Varex Imaging upgraded to Outperform from Perform at Oppenheimer
VREX Varex Imaging
$26.36 /

-0.7 (-2.59%)

VRAY ViewRay
$6.96 /

-0.05 (-0.71%)

TDY Teledyne
$437.11 /

-7.89 (-1.77%)

SYK Stryker
$273.25 /

+0.08 (+0.03%)

SNY Sanofi
$49.98 /

+0.125 (+0.25%)

SGEN Seagen
$177.70 /

+2.29 (+1.31%)

REGN Regeneron
$592.37 /

+16.45 (+2.86%)

PHG Philips
$47.69 /

-0.12 (-0.25%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

NVCR Novocure
$113.51 /

-5.91 (-4.95%)

NTRA Natera
$115.95 /

+0.2 (+0.17%)

NNOX Nano-X Imaging
$22.54 /

-0.55 (-2.38%)

NBTX Nanobiotix
$12.35 /

-0.3 (-2.37%)

MYGN Myriad Genetics
$30.66 /

-1.81 (-5.57%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

GRTX Galera Therapeutics
$1.88 /

+0.04 (+2.17%)

BSX Boston Scientific
$44.32 /

-0.17 (-0.38%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BIOC Biocept
$3.76 /

-0.08 (-2.08%)

BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

ARAY Accuray
$4.31 /

-0.08 (-1.82%)

  • 22
    Jul
  • 11
    Feb
  • 22
    Jan
  • 05
    Jan
  • 11
    Dec
SNY Sanofi
$49.98 /

+0.125 (+0.25%)

REGN Regeneron
$592.37 /

+16.45 (+2.86%)

PHG Philips
$47.69 /

-0.12 (-0.25%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

HTHIY Hitachi
$118.77 /

-0.71 (-0.59%)

DNA Ginkgo Bioworks
$14.46 /

+0.19 (+1.33%)

BSX Boston Scientific
$44.32 /

-0.17 (-0.38%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

VREX Varex Imaging
$26.36 /

-0.7 (-2.59%)

SYK Stryker
$273.25 /

+0.08 (+0.03%)

SNY Sanofi
$49.98 /

+0.125 (+0.25%)

SMMNY Siemens Healthineers
$34.66 /

-0.07 (-0.20%)

SGEN Seagen
$177.70 /

+2.29 (+1.31%)

REGN Regeneron
$592.37 /

+16.45 (+2.86%)

PHG Philips
$47.69 /

-0.12 (-0.25%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

NVCR Novocure
$113.51 /

-5.91 (-4.95%)

NTRA Natera
$115.95 /

+0.2 (+0.17%)

NNOX Nano-X Imaging
$22.54 /

-0.55 (-2.38%)

MYGN Myriad Genetics
$30.66 /

-1.81 (-5.57%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

GRTX Galera Therapeutics
$1.88 /

+0.04 (+2.17%)

DNA Ginkgo Bioworks
$14.46 /

+0.19 (+1.33%)

BSX Boston Scientific
$44.32 /

-0.17 (-0.38%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

TDY Teledyne
$437.11 /

-7.89 (-1.77%)

REGN Regeneron
$592.37 /

+16.45 (+2.86%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

NNOX Nano-X Imaging
$22.54 /

-0.55 (-2.38%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

GRTX Galera Therapeutics
$1.88 /

+0.04 (+2.17%)

DNA Ginkgo Bioworks
$14.46 /

+0.19 (+1.33%)

BSX Boston Scientific
$44.32 /

-0.17 (-0.38%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

Yesterday
Hot Stocks
Alkermes begins ARTISTRY-7 phase 3 trial » 07:12
10/26/21
10/26
07:12
10/26/21
07:12
ALKS

Alkermes

$31.81 /

+0.955 (+3.10%)

, MRK

Merck

$81.68 /

+0.52 (+0.64%)

, GOOG

Alphabet

$2,773.67 /

-1.81 (-0.07%)

Alkermes announced the…

Alkermes announced the initiation of ARTISTRY-7, a global phase 3, open-label, randomized trial evaluating the anti-tumor activity and safety of intravenously administered nemvaleukin alfa, or nemvaleukin, in combination with pembrolizumab, compared to investigator's choice chemotherapy, in patients with platinum-resistant ovarian cancer. Nemvaleukin, Alkermes' lead immuno-oncology candidate, is a novel, investigational, engineered interleukin-2 variant immunotherapy. As previously announced, ARTISTRY-7 is being conducted in collaboration with MSD, a tradename of Merck & Co. (MRK), which is providing KEYTRUDA for the study. In addition, Alkermes is working with The GOG Foundation, (GOOG) and the European Network of Gynaecological Oncological Trial groups, or ENGOT, to conduct the study. The FDA recently granted Fast Track designation to nemvaleukin in combination with pembrolizumab for the treatment of platinum-resistant ovarian cancer.

ShowHide Related Items >><<
MRK Merck
$81.68 /

+0.52 (+0.64%)

GOOG Alphabet
$2,773.67 /

-1.81 (-0.07%)

ALKS Alkermes
$31.81 /

+0.955 (+3.10%)

ALKS Alkermes
$31.81 /

+0.955 (+3.10%)

10/06/21 Jefferies
Alkermes upgraded to Buy from Hold at Jefferies
09/27/21 BofA
Alkermes takeover thesis 'highly speculative,' says BofA
09/10/21 Mizuho
Alkermes price target raised to $36 from $33 at Mizuho
09/02/21
Fly Intel: Top five analyst downgrades
MRK Merck
$81.68 /

+0.52 (+0.64%)

10/22/21 SVB Leerink
Merck price target raised to $105 from $104 at SVB Leerink
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/19/21 Evercore ISI
Atea's Phase 2 design disappoints, but drug has not failed, says Evercore ISI
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
GOOG Alphabet
$2,773.67 /

-1.81 (-0.07%)

10/22/21 Piper Sandler
Snap results raise uncertainty for digital advertising, says Piper Sandler
10/21/21 Stephens
Roku sits in 'more enviable' position in fight over YouTube TV, says Stephens
10/21/21 Mizuho
Alphabet price target raised to $3,100 from $3,000 at Mizuho
10/18/21 Wedbush
Wedbush continues to favor Google, Snap headed into quarterly results
MRK Merck
$81.68 /

+0.52 (+0.64%)

GOOG Alphabet
$2,773.67 /

-1.81 (-0.07%)

ALKS Alkermes
$31.81 /

+0.955 (+3.10%)

MRK Merck
$81.68 /

+0.52 (+0.64%)

GOOG Alphabet
$2,773.67 /

-1.81 (-0.07%)

MRK Merck
$81.68 /

+0.52 (+0.64%)

GOOG Alphabet
$2,773.67 /

-1.81 (-0.07%)

ALKS Alkermes
$31.81 /

+0.955 (+3.10%)

MRK Merck
$81.68 /

+0.52 (+0.64%)

Hot Stocks
Gilead and Merck to begin Phase 2 clinical study of islatravir and lenacapavir » 06:48
10/26/21
10/26
06:48
10/26/21
06:48
GILD

Gilead

$67.68 /

+0.455 (+0.68%)

, MRK

Merck

$81.68 /

+0.52 (+0.64%)

Gilead Sciences (GILD)…

Gilead Sciences (GILD) and Merck (MRK), known as MSD outside the U.S. and Canada, announced the start of a Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy. Through the collaboration the companies seek to build on their legacies of transforming HIV care by focusing on long-acting therapies, which may represent a meaningful innovation in HIV drug development. Both islatravir and lenacapavir have long half-lives and have demonstrated activity at low dosages in independent clinical studies, which support the development as an investigational combination regimen with long-acting formulations, both oral and injectable. The Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of Merck's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, in combination with Gilead's investigational capsid inhibitor, lenacapavir. The primary endpoint is the proportion of study participants with HIV-1 RNA viral load greater than or equal to 50 c/mL at Week 24.

ShowHide Related Items >><<
MRK Merck
$81.68 /

+0.52 (+0.64%)

GILD Gilead
$67.68 /

+0.455 (+0.68%)

GILD Gilead
$67.68 /

+0.455 (+0.68%)

10/19/21 Cowen
Gilead assumed with an Outperform at Cowen
09/23/21 Citi
Citi opens 'Positive Catalyst Watch' on Merck into Covid data
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
MRK Merck
$81.68 /

+0.52 (+0.64%)

10/22/21 SVB Leerink
Merck price target raised to $105 from $104 at SVB Leerink
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/19/21 Evercore ISI
Atea's Phase 2 design disappoints, but drug has not failed, says Evercore ISI
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
MRK Merck
$81.68 /

+0.52 (+0.64%)

GILD Gilead
$67.68 /

+0.455 (+0.68%)

MRK Merck
$81.68 /

+0.52 (+0.64%)

GILD Gilead
$67.68 /

+0.455 (+0.68%)

MRK Merck
$81.68 /

+0.52 (+0.64%)

GILD Gilead
$67.68 /

+0.455 (+0.68%)

MRK Merck
$81.68 /

+0.52 (+0.64%)

GILD Gilead
$67.68 /

+0.455 (+0.68%)

Conference/Events
American Society for Radiation Oncology to hold annual meeting » 04:55
10/26/21
10/26
04:55
10/26/21
04:55
ARAY

Accuray

$4.39 /

+0.02 (+0.46%)

, NVS

Novartis

$83.37 /

-1.515 (-1.78%)

, AZN

AstraZeneca

$61.75 /

-0.06 (-0.10%)

, BAYRY

Bayer

$14.16 /

+0.025 (+0.18%)

, BD

Budget Group

/

+

, BIOC

Biocept

$3.84 /

-0.02 (-0.52%)

, BSX

Boston Scientific

$44.49 /

-0.355 (-0.79%)

, BMY

Bristol-Myers

$57.84 /

+0.25 (+0.43%)

, EKTAY

Elekta

$11.49 /

-0.14 (-1.20%)

, GRTX

Galera Therapeutics

$1.84 /

+0.02 (+1.10%)

, DNA

Ginkgo Bioworks

$14.27 /

+1.145 (+8.72%)

, HTHIY

Hitachi

$119.48 /

+1.76 (+1.50%)

, MRK

Merck

$81.68 /

+0.52 (+0.64%)

, MYGN

Myriad Genetics

$32.47 /

+0.03 (+0.09%)

, NBTX

Nanobiotix

$12.35 /

-0.7 (-5.36%)

, NNOX

Nano-X Imaging

$23.08 /

+0.345 (+1.52%)

, NTRA

Natera

$115.78 /

+0.82 (+0.71%)

, NVCR

Novocure

$119.37 /

-1.5 (-1.24%)

, PHG

Philips

$47.81 /

-0.3 (-0.62%)

, REGN

Regeneron

$576.15 /

+3.42 (+0.60%)

, SNY

Sanofi

$49.85 /

+ (+0.00%)

, SGEN

Seagen

$175.45 /

+4.14 (+2.42%)

, SMMNY

Siemens Healthineers

$34.73 /

+0.342 (+0.99%)

, SYK

Stryker

$273.17 /

-2.71 (-0.98%)

, TDY

Teledyne

$444.97 /

-1.14 (-0.26%)

, VRAY

ViewRay

$7.01 /

+0.205 (+3.01%)

, VREX

Varex Imaging

$27.05 /

+0.12 (+0.45%)

63rd Annual ASTRO Meeting…

63rd Annual ASTRO Meeting 2021 will be held in Chicago on October 24-27.Webcast Link

ShowHide Related Items >><<
VRAY ViewRay
$7.01 /

+0.205 (+3.01%)

TDY Teledyne
$444.97 /

-1.14 (-0.26%)

SYK Stryker
$273.17 /

-2.71 (-0.98%)

SNY Sanofi
$49.85 /

+ (+0.00%)

SMMNY Siemens Healthineers
$34.73 /

+0.342 (+0.99%)

SGEN Seagen
$175.45 /

+4.14 (+2.42%)

REGN Regeneron
$576.15 /

+3.42 (+0.60%)

PHG Philips
$47.81 /

-0.3 (-0.62%)

NVS Novartis
$83.37 /

-1.515 (-1.78%)

NVCR Novocure
$119.37 /

-1.5 (-1.24%)

NTRA Natera
$115.78 /

+0.82 (+0.71%)

NNOX Nano-X Imaging
$23.08 /

+0.345 (+1.52%)

NBTX Nanobiotix
$12.35 /

-0.7 (-5.36%)

MYGN Myriad Genetics
$32.47 /

+0.03 (+0.09%)

MRK Merck
$81.68 /

+0.52 (+0.64%)

HTHIY Hitachi
$119.48 /

+1.76 (+1.50%)

GRTX Galera Therapeutics
$1.84 /

+0.02 (+1.10%)

EKTAY Elekta
$11.49 /

-0.14 (-1.20%)

DNA Ginkgo Bioworks
$14.27 /

+1.145 (+8.72%)

BSX Boston Scientific
$44.49 /

-0.355 (-0.79%)

BMY Bristol-Myers
$57.84 /

+0.25 (+0.43%)

BIOC Biocept
$3.84 /

-0.02 (-0.52%)

BAYRY Bayer
$14.16 /

+0.025 (+0.18%)

AZN AstraZeneca
$61.75 /

-0.06 (-0.10%)

ARAY Accuray
$4.39 /

+0.02 (+0.46%)

ARAY Accuray
$4.39 /

+0.02 (+0.46%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Northland
Accuray initiated with an Outperform at Northland
NVS Novartis
$83.37 /

-1.515 (-1.78%)

10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
10/08/21 UBS
Novartis price target lowered to CHF 92 from CHF 95 at UBS
09/29/21 Stifel
Blueprint Medicines rersumed with a Hold at Stifel
09/20/21 Deutsche Bank
Novartis downgraded to Sell from Hold at Deutsche Bank
AZN AstraZeneca
$61.75 /

-0.06 (-0.10%)

10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
10/11/21 Deutsche Bank
AstraZeneca price target raised to 10,500 GBp from 10,200 GBp at Deutsche Bank
09/29/21 Stifel
Zentalis initiated with a Buy at Stifel
09/29/21 H.C. Wainwright
H.C. Wainwright says Astra deal for Caelum to yield 'nice check' for Fortress
BAYRY Bayer
$14.16 /

+0.025 (+0.18%)

10/21/21 Morgan Stanley
Bayer price target raised to EUR 71 from EUR 70 at Morgan Stanley
08/09/21 Berenberg
Bayer price target lowered to EUR 60 from EUR 74 at Berenberg
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
BD Budget Group
/

+

BIOC Biocept
$3.84 /

-0.02 (-0.52%)

10/08/21 Brookline
Biocept assumed with a Buy at Brookline
BSX Boston Scientific
$44.49 /

-0.355 (-0.79%)

10/06/21 Piper Sandler
Boston Scientific acquisition of Baylis looks 'solid,' says Piper Sandler
09/22/21 Piper Sandler
Boston Scientific said unlikely to hit low end of Q3 sales outlook, notes Piper
09/14/21 Piper Sandler
CMS full repeal proposal of MCIT negative for med tech, says Piper Sandler
08/31/21 BTIG
Abbott price target raised to $136 from $126 at BTIG
BMY Bristol-Myers
$57.84 /

+0.25 (+0.43%)

10/25/21 SVB Leerink
Potential Bristol takeover of Aurinia makes strategic sense, says SVB Leerink
10/25/21 Citi
Bristol-Myers report of Aurinia approach 'looks credible,' says Citi
10/12/21 Morgan Stanley
Bristol-Myers price target lowered to $66 from $71 at Morgan Stanley
10/08/21 Morgan Stanley
Bristol-Myers' UC trial miss an incremental negative, says Morgan Stanley
EKTAY Elekta
$11.49 /

-0.14 (-1.20%)

08/27/21 JPMorgan
Elekta price target raised to SEK 95 from SEK 91 at JPMorgan
06/02/21 JPMorgan
Elekta price target raised to SEK 91 from SEK 82 at JPMorgan
04/27/21 JPMorgan
Elekta price target raised to SEK 82 from SEK 80 at JPMorgan
03/18/21 JPMorgan
Elekta downgraded to Underweight from Neutral at JPMorgan
GRTX Galera Therapeutics
$1.84 /

+0.02 (+1.10%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
DNA Ginkgo Bioworks
$14.27 /

+1.145 (+8.72%)

10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
10/13/21 Raymond James
Ginkgo Bioworks initiated with an Outperform at Raymond James
10/12/21 William Blair
Blair starts Ginkgo at Outperform on 'significant' competitive advantage
10/12/21 William Blair
Ginkgo Bioworks initiated with an Outperform at William Blair
HTHIY Hitachi
$119.48 /

+1.76 (+1.50%)

11/20/20 Goldman Sachs
Hitachi reinstated with a Sell at Goldman Sachs
MRK Merck
$81.68 /

+0.52 (+0.64%)

10/22/21 SVB Leerink
Merck price target raised to $105 from $104 at SVB Leerink
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/19/21 Evercore ISI
Atea's Phase 2 design disappoints, but drug has not failed, says Evercore ISI
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
MYGN Myriad Genetics
$32.47 /

+0.03 (+0.09%)

10/14/21 Cowen
Myriad Genetics coverage transferred at Cowen
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Myriad Genetics initiated with a Market Perform at Raymond James
06/03/21 Goldman Sachs
Myriad Genetics initiated with a Sell at Goldman Sachs
NBTX Nanobiotix
$12.35 /

-0.7 (-5.36%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
NNOX Nano-X Imaging
$23.08 /

+0.345 (+1.52%)

04/19/21 Ladenburg
Ladenburg starts Nano-X Imaging at Buy with $52 price target
04/19/21 Ladenburg
Nano-X Imaging initiated with a Buy at Ladenburg
02/01/21 Cantor Fitzgerald
Cantor Fitzgerald reiterates Overweight on Nano-X Imaging, lowers target to $67
NTRA Natera
$115.78 /

+0.82 (+0.71%)

10/19/21 Canaccord
Natera Prospera Lung launch to continue momentum, says Canaccord
10/14/21 Cowen
Natera coverage transferred at Cowen
08/31/21 Craig-Hallum
Natera seeks to challenge CareDx franchise with launch, says Craig-Hallum
08/09/21 Piper Sandler
Natera price target raised to $160 from $155 at Piper Sandler
NVCR Novocure
$119.37 /

-1.5 (-1.24%)

10/25/21 Piper Sandler
Novocure price target lowered to $195 from $235 at Piper Sandler
09/21/21 Piper Sandler
Novocure clinical update should come in next few weeks, says Piper Sandler
07/30/21 Mizuho
Novocure price target lowered to $200 from $229 at Mizuho
PHG Philips
$47.81 /

-0.3 (-0.62%)

10/25/21 Credit Suisse
Philips price target lowered to EUR 42 from EUR 49 at Credit Suisse
10/19/21 JPMorgan
Philips price target lowered to EUR 36.40 from EUR 40.90 at JPMorgan
10/19/21 Deutsche Bank
Philips price target lowered to EUR 42 from EUR 43 at Deutsche Bank
09/10/21 Barclays
Philips price target lowered to EUR 53 from EUR 54 at Barclays
REGN Regeneron
$576.15 /

+3.42 (+0.60%)

10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/22/21 H.C. Wainwright
Regeneron price target raised to $842 from $831 at H.C. Wainwright
10/14/21 H.C. Wainwright
H.C. Wainwright 'enthusiastic' on Regeneron, sees no barrier for REGEN-COV nod
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
SNY Sanofi
$49.85 /

+ (+0.00%)

10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
09/27/21 SVB Leerink
Sanofi upgraded to Outperform from Market Perform at SVB Leerink
SGEN Seagen
$175.45 /

+4.14 (+2.42%)

10/14/21 BTIG
Seagen assumed with a Neutral at BTIG
09/27/21 RBC Capital
Seagen price target raised to $154 from $148 at RBC Capital
05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
SMMNY Siemens Healthineers
$34.73 /

+0.342 (+0.99%)

10/13/21 UBS
Siemens Healthineers price target raised to EUR 54 from EUR 48 at UBS
10/01/21 Societe Generale
Siemens Healthineers downgraded to Hold at Societe Generale
10/01/21 Societe Generale
Siemens Healthineers downgraded to Hold from Buy at Societe Generale
09/10/21 Barclays
Siemens Healthineers price target raised to EUR 55 from EUR 49 at Barclays
SYK Stryker
$273.17 /

-2.71 (-0.98%)

09/14/21 Raymond James
Stryker resumed with a Market Perform at Raymond James
07/29/21 Argus
Stryker price target raised to $320 from $280 at Argus
07/28/21
Fly Intel: Top five analyst upgrades
07/28/21 SVB Leerink
Stryker price target raised to $300 from $290 at SVB Leerink
TDY Teledyne
$444.97 /

-1.14 (-0.26%)

07/30/21 Cowen
Teledyne price target raised to $525 from $500 at Cowen
06/08/21 Goldman Sachs
Teledyne reinstated with a Neutral at Goldman Sachs
05/25/21 BofA
Teledyne initiated with a Buy at BofA
04/29/21 Needham
Teledyne price target raised to $500 from $416 at Needham
VRAY ViewRay
$7.01 /

+0.205 (+3.01%)

10/19/21 Piper Sandler
ViewRay strength attributed to MIRAGE study recruiting halt, says Piper Sandler
10/14/21 B. Riley
ViewRay resumed with a Neutral at B. Riley
10/14/21 B. Riley
ViewRay resumed with a Neutral at B. Riley
06/25/21 Morgan Stanley
ViewRay upgraded to Equal Weight from Underweight at Morgan Stanley
VREX Varex Imaging
$27.05 /

+0.12 (+0.45%)

02/05/21 Oppenheimer
Varex Imaging upgraded to Outperform from Perform at Oppenheimer
VREX Varex Imaging
$27.05 /

+0.12 (+0.45%)

VRAY ViewRay
$7.01 /

+0.205 (+3.01%)

TDY Teledyne
$444.97 /

-1.14 (-0.26%)

SYK Stryker
$273.17 /

-2.71 (-0.98%)

SNY Sanofi
$49.85 /

+ (+0.00%)

SGEN Seagen
$175.45 /

+4.14 (+2.42%)

REGN Regeneron
$576.15 /

+3.42 (+0.60%)

PHG Philips
$47.81 /

-0.3 (-0.62%)

NVS Novartis
$83.37 /

-1.515 (-1.78%)

NVCR Novocure
$119.37 /

-1.5 (-1.24%)

NTRA Natera
$115.78 /

+0.82 (+0.71%)

NNOX Nano-X Imaging
$23.08 /

+0.345 (+1.52%)

NBTX Nanobiotix
$12.35 /

-0.7 (-5.36%)

MYGN Myriad Genetics
$32.47 /

+0.03 (+0.09%)

MRK Merck
$81.68 /

+0.52 (+0.64%)

GRTX Galera Therapeutics
$1.84 /

+0.02 (+1.10%)

BSX Boston Scientific
$44.49 /

-0.355 (-0.79%)

BMY Bristol-Myers
$57.84 /

+0.25 (+0.43%)

BIOC Biocept
$3.84 /

-0.02 (-0.52%)

BAYRY Bayer
$14.16 /

+0.025 (+0.18%)

AZN AstraZeneca
$61.75 /

-0.06 (-0.10%)

ARAY Accuray
$4.39 /

+0.02 (+0.46%)

  • 22
    Jul
  • 11
    Feb
  • 22
    Jan
  • 05
    Jan
  • 11
    Dec
SNY Sanofi
$49.85 /

+ (+0.00%)

REGN Regeneron
$576.15 /

+3.42 (+0.60%)

PHG Philips
$47.81 /

-0.3 (-0.62%)

NVS Novartis
$83.37 /

-1.515 (-1.78%)

MRK Merck
$81.68 /

+0.52 (+0.64%)

HTHIY Hitachi
$119.48 /

+1.76 (+1.50%)

DNA Ginkgo Bioworks
$14.27 /

+1.145 (+8.72%)

BSX Boston Scientific
$44.49 /

-0.355 (-0.79%)

BMY Bristol-Myers
$57.84 /

+0.25 (+0.43%)

BAYRY Bayer
$14.16 /

+0.025 (+0.18%)

AZN AstraZeneca
$61.75 /

-0.06 (-0.10%)

VREX Varex Imaging
$27.05 /

+0.12 (+0.45%)

SYK Stryker
$273.17 /

-2.71 (-0.98%)

SNY Sanofi
$49.85 /

+ (+0.00%)

SMMNY Siemens Healthineers
$34.73 /

+0.342 (+0.99%)

SGEN Seagen
$175.45 /

+4.14 (+2.42%)

REGN Regeneron
$576.15 /

+3.42 (+0.60%)

PHG Philips
$47.81 /

-0.3 (-0.62%)

NVS Novartis
$83.37 /

-1.515 (-1.78%)

NVCR Novocure
$119.37 /

-1.5 (-1.24%)

NTRA Natera
$115.78 /

+0.82 (+0.71%)

NNOX Nano-X Imaging
$23.08 /

+0.345 (+1.52%)

MYGN Myriad Genetics
$32.47 /

+0.03 (+0.09%)

MRK Merck
$81.68 /

+0.52 (+0.64%)

GRTX Galera Therapeutics
$1.84 /

+0.02 (+1.10%)

DNA Ginkgo Bioworks
$14.27 /

+1.145 (+8.72%)

BSX Boston Scientific
$44.49 /

-0.355 (-0.79%)

BMY Bristol-Myers
$57.84 /

+0.25 (+0.43%)

BAYRY Bayer
$14.16 /

+0.025 (+0.18%)

AZN AstraZeneca
$61.75 /

-0.06 (-0.10%)

TDY Teledyne
$444.97 /

-1.14 (-0.26%)

REGN Regeneron
$576.15 /

+3.42 (+0.60%)

NVS Novartis
$83.37 /

-1.515 (-1.78%)

NNOX Nano-X Imaging
$23.08 /

+0.345 (+1.52%)

MRK Merck
$81.68 /

+0.52 (+0.64%)

GRTX Galera Therapeutics
$1.84 /

+0.02 (+1.10%)

DNA Ginkgo Bioworks
$14.27 /

+1.145 (+8.72%)

BSX Boston Scientific
$44.49 /

-0.355 (-0.79%)

BMY Bristol-Myers
$57.84 /

+0.25 (+0.43%)

AZN AstraZeneca
$61.75 /

-0.06 (-0.10%)

Monday
Conference/Events
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 09:43
10/25/21
10/25
09:43
10/25/21
09:43
MRK

Merck

$81.16 /

+ (+0.00%)

Large Cap Biopharma…

Large Cap Biopharma Analysts Kim & Chen, along with Bhavesh Shah, RPH, BCOP, Senior Director of Hematology, Oncology & Specialty Pharmacy at Boston Medical Center, discuss discounted pricing strategies for PD-1/PD-L1 Inhibitors on an Analyst/Industry conference call to be held on October 29 at 1 pm.

ShowHide Related Items >><<
MRK Merck
$81.16 /

+ (+0.00%)

MRK Merck
$81.16 /

+ (+0.00%)

10/22/21 SVB Leerink
Merck price target raised to $105 from $104 at SVB Leerink
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/19/21 Evercore ISI
Atea's Phase 2 design disappoints, but drug has not failed, says Evercore ISI
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
MRK Merck
$81.16 /

+ (+0.00%)

MRK Merck
$81.16 /

+ (+0.00%)

MRK Merck
$81.16 /

+ (+0.00%)

MRK Merck
$81.16 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.